Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Dianthus Therapeutics. According to TipRanks, Katkhuda has an average return of 30.9% and a 52.19% success rate on recommended stocks.
In addition to LifeSci Capital, MoonLake Immunotherapeutics also received a Buy from Needham’s Serge Belanger in a report issued on May 12. However, on May 11, Goldman Sachs maintained a Sell rating on MoonLake Immunotherapeutics (NASDAQ: MLTX).
Based on MoonLake Immunotherapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $69.71 million. In comparison, last year the company had a GAAP net loss of $39.94 million
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MLTX in relation to earlier this year. Last month, Jorge Santos da Silva, the CEO of MLTX sold 150,000.00 shares for a total of $2,752,162.86.
